1,463 results match your criteria Paronychia


Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience.

Curr Oncol 2018 Oct 31;25(5):e385-e390. Epub 2018 Oct 31.

Princess Margaret Cancer Centre, University Health Network, Toronto, ON.

Background: Afatinib, an irreversible epidermal growth factor receptor tyrosine kinase inhibitor (egfr tki), is approved for first-line therapy in advanced mutation-positive non-small-cell lung cancer (nsclc) and has previously demonstrated activity after failure of chemotherapy and reversible egfr tkis, with improved response and progression-free survival, compared with placebo. Outcomes in pretreated patients with advanced nsclc receiving afatinib through a Canadian special access program (sap) are reported here.

Methods: Patients with nsclc progressing after at least 1 line of chemotherapy and an egfr tki were eligible to enrol in the sap. Read More

View Article
October 2018
3 Reads

Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.

Am J Clin Dermatol 2018 Nov;19(Suppl 1):31-39

Institut Universitaire du Cancer Toulouse - Oncopole, 1 avenue Irène Joliot-Curie, 31059, TOULOUSE Cedex 9, France.

Targeted therapies and immunotherapies are associated with a wide range of dermatologic adverse events (dAEs) resulting from common signaling pathways involved in malignant behavior and normal homeostatic functions of the epidermis and dermis. Dermatologic toxicities include damage to the skin, oral mucosa, hair, and nails. Acneiform rash is the most common dAE, observed in 25-85% of patients treated by epidermal growth factor receptor and mitogen-activated protein kinase kinase inhibitors. Read More

View Article
November 2018
12 Reads

Phase I trial of afatinib and 3-weekly trastuzumab with optimal anti-diarrheal management in patients with HER2-positive metastatic cancer.

Cancer Chemother Pharmacol 2018 Dec 22;82(6):979-986. Epub 2018 Oct 22.

Institut Universitaire du Cancer de Toulouse, Oncopôle, 1 avenue Irène Joliot-Curie, 31059, Toulouse Cedex 9, France.

Background: Trastuzumab is the mainstay of therapy for patients with HER2-positive breast and gastric cancer but resistance frequently occurs. Afatinib, an irreversible oral ErbB family blocker, shows clinical activity in trastuzumab-refractory HER2-positive metastatic breast cancer.

Materials And Methods: This phase I study used a modified 3 + 3 dose escalation design to determine the maximum tolerated dose (MTD) of oral once-daily afatinib in combination with 3-weekly intravenous trastuzumab (8 mg/kg week 1; 6 mg/kg 3-weekly thereafter) for patients with confirmed advanced or metastatic HER2-positive cancer. Read More

View Article
December 2018
11 Reads

Adverse cutaneous effects of neratinib.

J Dermatolog Treat 2018 Nov 28:1-2. Epub 2018 Nov 28.

a Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.

Neratinib is a tyrosine kinase inhibitor that was FDA-approved for extended adjuvant treatment in adults with human epidermal growth factor receptors-2 (HER-2) positive breast cancer in 2017. Due to the novelty of the drug, there are no current reports in the literature of adverse cutaneous effects associated with neratinib therapy. We present a case of a woman on neratinib for HER-2 positive infiltrating ductal carcinoma of the right breast who presented to the dermatology clinic with changes to the fingernails, acne, and a rash on the face. Read More

View Article
November 2018

Case series showing the efficacy of 5-aminolaevulinic acid photodynamic therapy for epidermal growth factor receptor inhibitor-induced paronychia and pyogenic granuloma-like lesions.

Br J Dermatol 2018 Oct 9. Epub 2018 Oct 9.

Section of Dermatology, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.

View Article
October 2018
1 Read

Papulopustules and paronychia in a lung carcinoma.

Eur J Intern Med 2018 Oct 5. Epub 2018 Oct 5.

Department of Dermatology, Venereology, and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India. Electronic address:

View Article
October 2018
10 Reads

Coexistence of Fungal Infections in Psoriatic Nails and their Correlation with Severity of Nail Psoriasis.

Indian Dermatol Online J 2018 Sep-Oct;9(5):314-317

Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Background: Nail involvement in psoriasis is often complicated by concomitant fungal infections. The aim of this study was to investigate the prevalence of fungal infections in nail psoriasis and correlate it with the severity of nail psoriasis.

Materials And Methods: This retrospective study included patients with nail psoriasis aged ≥18 years with at least one fingernail and one toenail involvement who were treated at Siriraj Hospital from September 2012 to January 2014. Read More

View Article
September 2018
9 Reads

Systemic Drug-induced Chronic Paronychia and Periungual Pyogenic Granuloma.

Authors:
Uwe Wollina

Indian Dermatol Online J 2018 Sep-Oct;9(5):293-298

Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Academic Teaching Hospital of the Technical University of Dresden, Dresden, Germany.

Paronychia is a painful inflammatory disorder of the nail fold. Periungual pyogenic granuloma - a benign vascular tumor of the capillaries - can develop as a complication of paronychia. We report both, paronychia and periungual pyogenic granuloma, as possible adverse events during systemic drug-therapy. Read More

View Article
September 2018
5 Reads

Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the T790M Mutation After Failure of Initial EGFR-TKI Treatment.

Anticancer Res 2018 Sep;38(9):5231-5237

Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

Background/aim: The aim of this study was to evaluate the safety and efficacy of osimertinib for elderly patients, since the data remain limited.

Patients And Methods: A total of 77 patients with advanced non-small cell lung cancer (NSCLC) harboring the epidermal growth factor receptor (EGFR) T790M mutation and treated with osimertinib were reviewed. Efficacy and safety indicators, such as EGFR-tyrosine kinase inhibitor (TKI)-related adverse events (AEs) and osimertinib-associated hematotoxicity, were evaluated in elderly patients (elderly group, EG; age, ≥75 years) by comparing them with younger patients (non-EG; aged <75 years). Read More

View Article
September 2018
2 Reads

Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study).

Cancer 2018 Oct 7;124(19):3830-3838. Epub 2018 Sep 7.

Department of Medical Oncology, Takarazuka City Hospital, Takarazuka, Japan.

Background: Preclinical studies suggested that the addition of bevacizumab could overcome acquired resistance (AR) to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The aim of this study was to evaluate the clinical efficacy and safety of a combination of afatinib and bevacizumab after AR.

Methods: Patients with EGFR-mutant non-small cell lung cancer after AR were enrolled during any line of therapy. Read More

View Article
October 2018
2 Reads

Retronychia.

An Bras Dermatol 2018 Sep-Oct;93(5):707-711

Dermatology Department, Hospital do Servidor Público Municipal de São Paulo, São Paulo (SP), Brazil.

Retronychia is a recently described disorder caused by ingrowth of the proximal nail plate into the proximal nail fold. It is suspected when there is persistent paronychia, particularly in the setting of trauma. This disease is probably underdiagnosed due to limited knowledge among dermatologists and the presence of incomplete clinical forms. Read More

View Article
October 2018
3 Reads

Involvement of Nail Apparatus in Pemphigus Vulgaris in Ethnic Poles Is Infrequent.

Front Med (Lausanne) 2018 14;5:227. Epub 2018 Aug 14.

Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland.

Pemphigus vulgaris lesions have a tendency to localize around natural body orifices. The aim here was to analyze the involvement of nail apparatus in pemphigus vulgaris. Sixty seven ethnic Poles suffering from pemphigus vulgaris on photographic files archiving initial presentation were retrospectively evaluated. Read More

View Article
August 2018
5 Reads

Onychomycosis caused by Aspergillus subramanianii.

J Dermatol 2018 Nov 25;45(11):1362-1366. Epub 2018 Aug 25.

Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.

We describe a case of a 23-year-old female patient with no apparent underlying diseases. She showed a discoloration of the proximal portion of the left big toenail with paronychia. Direct microscopy revealed septate hyphae with conidiophores, and a periodic acid-Schiff-stained nail specimen revealed septate hyphae branching at angles of approximately 45°. Read More

View Article
November 2018
7 Reads

Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy

Asian Pac J Cancer Prev 2018 Aug 24;19(8):2325-2330. Epub 2018 Aug 24.

Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, Japan. Email:

Background: Cetuximab-induced skin disorder is common in colorectal cancer (CRC), and is known to affect prolonged overall survival (OS). Patients with left-sided CRC survive longer than those with right-sided CRC, among those treated with combination cetuximab and chemotherapy. However, no study has evaluated patient prognosis in terms of OS and progression-free survival (PFS) in relation to both tumor location and skin disorder. Read More

View Article
August 2018
2 Reads

Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib.

Support Care Cancer 2018 Aug 16. Epub 2018 Aug 16.

Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, Canada.

Purpose: Afatinib is a standard first-line therapy for advanced EGFR-positive NSCLC. We implemented a pharmacist-led proactive follow-up algorithm to identify and manage early afatinib-related adverse events (AEs).

Methods: We conducted a retrospective chart review of all patients treated with afatinib after implementation of the algorithm at the Sunnybrook Odette Cancer Centre (Toronto, ON, Canada) from April 1, 2015 to July 31, 2016. Read More

View Article

Cost-effectiveness and safety of the molecular targeted drugs afatinib, gefitinib and erlotinib as first-line treatments for patients with advanced EGFR mutation-positive non-small-cell lung cancer.

Mol Clin Oncol 2018 Aug 30;9(2):201-206. Epub 2018 May 30.

Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu 503-8502, Japan.

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including gefitinib, erlotinib and afatinib are standard first-line treatments for EGFR gene mutation-positive non-small cell lung cancer. The present study aimed to compare the cost-effectiveness of using erlotinib, afatinib or gefitinib. The safety of EGFR-TKIs was also investigated. Read More

View Article
August 2018
13 Reads

Protecting the diseased digits. Home remedy for the homemaker.

J Am Acad Dermatol 2018 Aug 3. Epub 2018 Aug 3.

Senior Consultant Dermatologist, KIMS AL SHIFA Super Speciality Hospital, Perinthalmanna, Kerala, 679 322. India. Electronic address:

View Article
August 2018
1 Read

Imiquimod-induced hypopigmentation following treatment of periungual verruca vulgaris.

Cutis 2018 Jun;101(6):466-468

Bay Pines VA Healthcare System, St. Petersburg, Florida, USA.

Imiquimod is a topical immunomodulating medication approved by the US Food and Drug Administration for the treatment of condyloma acuminata, actinic keratoses (AKs), and superficial basal cell carcinoma (BCC). Imiquimod commonly is used off label for its antiviral and antitumoral effects. We present a case of a 51-year-old man with vitiligolike depigmentation following treatment of periungual verruca vulgaris with imiquimod therapy. Read More

View Article
June 2018
1 Read

Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.

J Oncol Pharm Pract 2018 Jul 25:1078155218788707. Epub 2018 Jul 25.

3 Division of Hematology and Cellular Therapy, Allegheny Health Network, Pittsburgh, USA.

Background Ibrutinib, a Bruton's tyrosine kinase inhibitor has reformed the treatment of various B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Although generally well tolerated, here we describe our institutional experience of unique adverse effects encountered with the use of ibrutinib in patients with B-cell lymphomas. Methods This is a retrospective observational study done at a tertiary care facility, to evaluate adverse events in patients with B-cell malignancies on treatment with ibrutinib between 2014 and 2018. Read More

View Article
July 2018
3 Reads

A case report of toxic epidermal necrolysis associated with AZD-9291.

Drug Des Devel Ther 2018 11;12:2163-2167. Epub 2018 Jul 11.

Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, The People's Republic of China,

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a strain of small molecule inhibitors mainly used to treat the metastatic non-small cell lung cancer. Their predominant adverse effect is skin toxicity, usually manifested as acneiform rash, skin fissure, xerosis, and paronychia. Severe epidermal necrosis and exfoliation rarely occur. Read More

View Article
December 2018
15 Reads

Hand Infections.

J Hand Surg Am 2018 Jul 13. Epub 2018 Jul 13.

Department of Orthopedic Surgery, Baylor College of Medicine, Texas Children's Hospital, Houston, TX. Electronic address:

Infections are common in hand surgery and proper management is important to achieve optimal outcomes. Although most cases are not urgent, less common, severe infections such as flexor tenosynovitis and necrotizing fasciitis require urgent identification with both medical and surgical management. It is common for diagnoses to be missed or delayed because clinical and laboratory indicators are often variably present. Read More

View Article
July 2018
11 Reads

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer.

Cancer Chemother Pharmacol 2018 Sep 20;82(3):407-418. Epub 2018 Jun 20.

Cancer Medicine Division, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA.

Purpose: The phase I study characterized the safety, pharmacokinetics, anti-tumor activity, and recommended phase II dose/schedule of LY3164530 in patients with advanced or metastatic cancer.

Methods: Patients received LY3164530 on days 1 and 15 (Schedule 1: 300, 600, 1000, and 1250 mg) or Days 1, 8, 15, and 22 (Schedule 2: 500 and 600 mg) of each 28 days cycle. Dose escalation used a modified toxicity probability interval model. Read More

View Article
September 2018
3 Reads

Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.

Oncology 2018 14;95(4):251-256. Epub 2018 Jun 14.

Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan.

Purpose: The purpose of the study was to evaluate the site of paronychia in patients with non-small cell lung cancer harboring an epidermal growth factor receptor (EGFR) gene activating mutation who were treated with EGFR tyrosine kinase inhibitors (EGFR TKIs).

Patients And Methods: The study included 55 patients with non-small-cell lung cancer who were treated with an EGFR TKIs. Resulting all toxicities were graded using the Common Terminology Criteria for Adverse Events version 4. Read More

View Article
October 2018
9 Reads

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.

Cancer Res Treat 2018 Jun 13. Epub 2018 Jun 13.

Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Purpose: We tried to evaluate whether there is any specific features in treatment outcomes of first-line afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), compared with gefitinib or erlotinib.

Materials And Methods: We analyzed patients treated with first-line afatinib, gefitinib, or erlotinib for advanced EGFR-mutant NSCLC at Samsung Medical Center between 2014 and 2016.

Results: In total, 467 patients received first-line afatinib (n=165), gefitinib (n=230), or erlotinib (n=72). Read More

View Article
June 2018
4 Reads

Using a novel scoring system for paronychia related to oncologic treatments (SPOT) for assessing paronychia severity and its correlation with pain index and quality of life.

J Eur Acad Dermatol Venereol 2018 Jun 12. Epub 2018 Jun 12.

Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.

Background: Oncologic treatments may lead to the development of paronychia, which may cause severe pain and disability. However, a detailed objective scoring system is lacking.

Objective: To develop an objective scoring system to quantify the severity of paronychia and also examine the correlation of this score with a pain index and patients' quality of life. Read More

View Article
June 2018
2 Reads

Coagulase-Negative Staphylococcus Skin and Soft Tissue Infections.

Am J Clin Dermatol 2018 Oct;19(5):671-677

Department of Dermatology, University of California San Diego, 10991 Twinleaf Court, La Jolla, San Diego, CA, 92131-3642, USA.

Coagulase-negative staphylococcus organisms may be normal flora of human skin, however these bacteria can also be pathogens in skin and soft tissue infections. A summary of skin and soft tissue infections caused by coagulase-negative staphylococcus species is provided in this review. We conducted a search of the PubMed database using the following terms: abscess, auricularis, biofilm, capitis, cellulitis, coagulase, contaminant, cyst, draining, epidermidis, felon, folliculitis, furuncle, haemolyticus, hominis, indolent, infection, lugdunensis, mecA, microbiome, negative, osteomyelitis, paronychia, saprophyticus, skin, simulans, sinus, soft, staphylococcus, systemic, tissue, virulence, virulent, and vulvar. Read More

View Article
October 2018
23 Reads

Ingrown Toenails During Chemotherapy and Stem Cell Transplantation in Children With Hematological Malignancies and Solid Tumors.

J Pediatr Hematol Oncol 2018 May 10. Epub 2018 May 10.

Department of Hematology/Oncology for Children and Adolescents, Sapporo Hokuyu Hospital, Sapporo, Japan.

Background: At our institution, we noted that children with hematological malignancies and solid tumors often suffered from ingrown toenails (IGTNs) during hospitalization for chemotherapy and stem cell transplantation. However, only few reports have dealt with IGTNs in the above setting.

Procedure: Between August 2007 and July 2017, 180 children who received treatment for hematological malignancies and solid tumors at our institute were enrolled in this study. Read More

View Article
May 2018
4 Reads

Management and grading of EGFR inhibitor-induced cutaneous toxicity.

Future Oncol 2018 Oct 4;14(24):2531-2541. Epub 2018 May 4.

Department of Medical/Clinical Oncology, Christie Hospital, 550 Wilmslow Road, Manchester, UK.

Cutaneous toxicities associated with EGFR inhibitors (EGFRIs) have a significant impact on patient treatment continuation, quality of life and healthcare resource utilization. This paper reviews the current prophylaxis and management of EGFRI-induced cutaneous toxicities in patients with colorectal cancer, and combines these findings with the authors' clinical expertise to define a novel algorithm for healthcare professionals managing patients receiving EGFRIs. This tool includes a grading system based on the location, severity and psychological impact, and provides a standard prescription pack, advice on prophylaxis/self-management of cutaneous symptoms for patients initiating EGFRIs, and essential guidance on subsequent review and treatment escalation. Read More

View Article
October 2018
9 Reads

Onychophagia Induced Melanonychia, Splinter Hemorrhages, Leukonychia, and Pterygium Inversum Unguis Concurrently.

Case Rep Dermatol Med 2018 30;2018:3230582. Epub 2018 Jan 30.

Department of Dermatology, Suleyman Demirel University Faculty of Medicine, Isparta, Turkey.

Onychophagia, which refers to compulsive nail-biting behavior, is common among children and young adults. Onychophagia can cause destruction to the cuticle and nail plate, leading to shortening of nails, chronic paronychia, and secondary infections. Relatively uncommon effects include pigmentary changes, such as longitudinal melanonychia and splinter hemorrhages. Read More

View Article
January 2018
10 Reads

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

Oncologist 2018 Aug 12;23(8):891-899. Epub 2018 Apr 12.

Memorial Sloan Kettering Cancer Center, New York City, New York, USA

Dermatologic adverse events (dAEs) are common with the use of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. First- and second-generation agents (erlotinib, gefitinib, and afatinib) are frequently associated with acneiform rash, pruritus, xerosis, and paronychia; the incidence and characterization of these dAEs have been well described. However, there is evidence that the dAE profile is different with third-generation EGFR-TKIs. Read More

View Article
August 2018
1 Read

Proximal Subungual Onychomycosis in the Immunocompetent: A Case Report and Review of the Literature.

J Drugs Dermatol 2018 Apr;17(4):475-478

Proximal subungual onychomycosis (PSO), which predominantly involves the nail plate from the proximal nail fold, is the rarest form of onychomycosis. Classically associated with an immunocompromised state, PSO is an uncommon diagnosis in individuals without immunodeficiency. We present a case of a healthy 51-year-old man, who presented with a three-month history of white discoloration of multiple toenails. Read More

View Article
April 2018
17 Reads

Efficacy of gefitinib and radiotherapy combination in Indonesian patients with lung adenocarcinoma.

Rom J Intern Med 2018 Sep;56(3):173-181

Department of Pulmonology and Respiratory Medicine, Faculty of Medicine Universitas Indonesia, Persahabatan National Respiratory Referral Hospital, Jalan Persahabatan Raya No. 1, Rawamangun,Jakarta, Indonesia.

Introduction: Combinations of gefitinib and radiotherapy have been observed to have synergistic and anti-proliferative effects on lung cancer in vitro. In the clinical setting, patients who presented with respiratory difficulties such as superior vena cava syndrome (SVCS), radiotherapy should be given immediately to address the emergency while waiting for the results of epidermal growth factor receptor (EGFR) mutation test. However, there has been no study that described the role of radio-therapy in Indonesian patients with EGFR-mutant lung adenocarcinoma. Read More

View Article
September 2018
13 Reads

Chronic Paronychia and Onychomadesis in Pemphigus Vegetans: An Unusual Presentation in a Rare Autoimmune Disease.

Case Rep Med 2018 11;2018:5980937. Epub 2018 Jan 11.

Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Pemphigus vegetans is a rare variant of deep acantholytic pemphigus which usually presents with vesiculobullous rash and vegetative plaques on the folds. We report a case of pemphigus vegetans patient who presented with rashes on tips of fingers and toes resembling paronychia and onychomadesis that misled the diagnosis for months. The final diagnosis of Hallopeau-type pemphigus vegetans was made based on histopathology and direct immunofluorescence studies. Read More

View Article
January 2018
3 Reads

Clinical impact of minocycline on afatinib-related rash in patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.

Respir Investig 2018 Mar 21;56(2):179-183. Epub 2017 Dec 21.

Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi Ward, Hamamatsu, Shizuoka 431-3192, Japan. Electronic address:

Background: The management of skin toxicity is crucial for efficient afatinib treatment, but the role of tetracycline class antibiotics (TCs) in managing these rashes is relatively unknown.

Methods: We reviewed the clinical records of patients who were administered afatinib for the treatment of non-small cell lung cancer harboring epidermal growth factor receptor mutations between October 2014 and November 2016. Twenty-five patients, who received TCs for the management of afatinib-related skin disorders, were enrolled. Read More

View Article
March 2018
5 Reads

Febrile neutropenia with bacterial paronychia.

Clin Case Rep 2018 03 26;6(3):543-544. Epub 2018 Jan 26.

Department of Thoracic Oncology National Hospital Organization Toneyama National Hospital Toyonaka Osaka 560-8552 Japan.

The symptoms of infection can be minimal or absent in patients with febrile neutropenia at first. The focal site of infection, which may be the main cause of a fever or be a complication of neutropenia, can develop as neutrophils increase during the clinical course of febrile neutropenia. Read More

View Article
March 2018
2 Reads

The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors.

Postepy Dermatol Alergol 2017 Oct 31;34(5):418-428. Epub 2017 Oct 31.

Chair of Dermatology, Sexually Transmitted Diseases and Immunodermatology, Nicolaus Copernicus University in Torun, Faculty of Medicine in Bydgoszcz, Poland.

Overexpression of the epidermal growth factor receptor (EGFR) is found in many cancers, including those of the head and neck area, non-small-cell lung cancer, and colorectal, cervical, prostate, breast, ovary, stomach, and pancreatic cancer. The EGFR inhibitors are used at present in the treatment of such cancers. Skin lesions that develop during and after cancer treatment may be due to specific cytostatics, molecular-targeted drugs, radiation therapy, complementary therapy, or the cancer itself, and hence knowledge is essential to distinguish between them. Read More

View Article
October 2017
5 Reads

Purulent Pericarditis Due to Paronychia in a 16-Month-Old Child: A Nail-Biting Story.

World J Pediatr Congenit Heart Surg 2018 Jan 1:2150135117742651. Epub 2018 Jan 1.

1 Division of Cardiology, Carman and Ann Adams Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI, USA.

Purulent pericarditis is a rare infectious disease with significant mortality, even in the modern antibiotic era. The presenting signs can often be subtle and patients can deteriorate rapidly with cardiac tamponade. We report a previously healthy 16-month-old female who developed purulent pericarditis associated with paronychia and sepsis caused by methicillin-sensitive Staphylococcus aureus. Read More

View Article
January 2018
1 Read

Skin Rash Can Be a Useful Marker for Afatinib Efficacy.

Anticancer Res 2018 03;38(3):1783-1788

Department of Thoracic Oncology, Osaka Prefectural Hospital Organization Osaka Habikino Medical Center, Osaka, Japan.

Background/aim: Although afatinib has a strong efficacy, it can be toxic; hence, we aimed to determine markers of response to afatinib in order to assess prognosis.

Patients And Methods: Information on clinical background, therapeutic effects, and adverse events was collected retrospectively at one Institution from patients treated with afatinib as initial epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI). We examined the relationship between different adverse events and their effects on prognosis. Read More

View Article
March 2018
5 Reads

Retronychia a little-known cause of paronychia: A report of two cases in adolescent patients.

Pediatr Dermatol 2018 May 26;35(3):e144-e146. Epub 2018 Feb 26.

Department of Dermatology, University General Hospital of Alicante, Alicante, Spain.

Retronychia is a clinical condition resulting from embedding of the nail plate into the proximal nail fold. We report two adolescent girls, 14 and 16 years of age, with a history of chronic proximal paronychia of the great toe, one of them developing osteomyelitis. After failure of treatment with several systemic antibiotics, nail avulsion was performed, leading us to the diagnosis of retronychia and with rapid and complete resolution of symptoms in both cases. Read More

View Article
May 2018
2 Reads

Retronychia: an underdiagnosed disease.

Dermatol Online J 2017 Jul 15;23(7). Epub 2017 Jul 15.

Department of Dermatology, Hospital Clínico Universitario de Valladolid, Spain.

Retronychia is a recently described cause of ingrowth of the nail plate on the ventral surface of the proximal nail fold. Clinical features are repeated episodes of proximal paronychia, nail plate thickening, and occasionally granulation tissue emergence. The usual treatments for paronychia such as antibiotics and antifungals are ineffective in these cases. Read More

View Article
July 2017
1 Read

Overview of current systemic management of EGFR-mutant NSCLC.

Ann Oncol 2018 Jan;29(suppl_1):i3-i9

Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong.

Front-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) therapy is the standard of care for lung cancer patients with sensitising EGFR mutations (exon 19 deletion or L858R mutation). Several phase III studies have demonstrated the superiority of gefitinib, erlotinib (first generation of TKIs) or afatinib (second generation) to chemotherapy in progression-free survival and response rates. Drug-related toxicities, such as diarrhoea, acneiform skin rash, mucositis, and paronychia, are frequently encountered in patients who receive EGFR TKIs. Read More

View Article
January 2018
2 Reads

The microbial flora of taxane therapy-associated nail disease in cancer patients.

J Am Acad Dermatol 2018 03;78(3):607-609

Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address:

View Article
March 2018
3 Reads

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations.

Med Oncol 2018 Feb 8;35(3):34. Epub 2018 Feb 8.

Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, 5, Zaifu-cho, Hirosaki, 036-8562, Japan.

This phase I trial was conducted to determine the maximum tolerated dose (MTD) and recommended dose of afatinib for phase II trial in elderly patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. The study used a standard 3 + 3 dose escalation design. Patients aged 75 years or older with advanced NSCLC harboring EGFR mutations were enrolled. Read More

View Article
February 2018
3 Reads

Different Toxicity of Cetuximab and Panitumumab in Metastatic Colorectal Cancer Treatment: A Systematic Review and Meta-Analysis.

Oncology 2018 23;94(4):191-199. Epub 2018 Jan 23.

Oncology Unit, Oncology Department, ASST Ospedale di Cremona, Cremona, Italy.

Background: Over the last few years only one large randomized phase III study has tried to prospectively assess the safety of cetuximab and panitumumab in a head-to-head comparison. Despite the similar overall toxicity profile, cetuximab and panitumumab retain peculiar safety characteristics that deserve to be deeply investigated.

Methods: We conducted a systematic review for randomized trials in PubMed, the Cochrane Central Register of Controlled Trials, SCOPUS, Web of Science, and EMBASE using the terms ("cetuximab" or "panitumumab") AND ("colorectal cancer" OR "colorectal carcinoma"). Read More

View Article
March 2018
6 Reads

Toe keloid after nail extraction treated with surgical excision: A case report.

Medicine (Baltimore) 2017 Dec;96(51):e9373

Department of Plastic Surgery, Peking Union Medical College Hospital.

Rationale: In this study, a case of toe keloid after nail extraction is presented, in which the keloids on both toes were resected by surgical excision. Keloids (from the Greek word meaning "crab's claw") are fibrous growths that extend beyond the original area of injury to involve the adjacent normal skin. In general, keloid tendencies appear to be regionally isolated to keloid-prone areas, such as the chest, ears, and deltoid regions, whereas the hands and feet are usually spared, which is why this case is meaningful. Read More

View Article
December 2017
1 Read

Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management.

Authors:
Eckart Haneke

Psoriasis (Auckl) 2017 16;7:51-63. Epub 2017 Oct 16.

Department of Dermatology, Inselspital, University of Bern, Bern, Switzerland.

Psoriasis is the skin disease that most frequently affects the nails. Depending on the very nail structure involved, different clinical nail alterations can be observed. Irritation of the apical matrix results in psoriatic pits, mid-matrix involvement may cause leukonychia, whole matrix affection may lead to red lunulae or severe nail dystrophy, nail bed involvement may cause salmon spots, subungual hyperkeratosis, and splinter hemorrhages, and psoriasis of the distal nail bed and hyponychium causes onycholysis whereas that of the proximal nail fold causes psoriatic paronychia. Read More

View Article
October 2017
5 Reads

Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.

Cancer Sci 2018 Apr 27;109(4):1177-1184. Epub 2018 Feb 27.

Research and Development, AstraZeneca K.K, Osaka, Japan.

Osimertinib is a potent, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) selective for EGFR-TKI sensitizing (EGFRm) and T790M resistance mutations. The primary objective of the cytology cohort in the AURA study was to investigate safety and efficacy of osimertinib in pretreated Japanese patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC), with screening EGFR T790M mutation status determined from cytology samples. The cytology cohort was included in the Phase I dose expansion component of the AURA study. Read More

View Article
April 2018
11 Reads

Topical betaxolol for treating relapsing paronychia with pyogenic granuloma-like lesions induced by epidermal growth factor receptor inhibitors.

J Am Acad Dermatol 2018 06 12;78(6):e143-e144. Epub 2018 Jan 12.

Department of Dermatology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. Electronic address:

View Article
June 2018
16 Reads

Nail changes in autoimmune blistering disorders: A case-control study.

Indian J Dermatol Venereol Leprol 2018 May-Jun;84(3):373

Department of Dermatology, Venereology and Leprosy, Yenepoya Medical College, Yenepoya University, Mangalore, Karnataka, India.

Background: Pemphigus and pemphigoid disorders produce blistering cutaneous lesions. Earlier case reports state that nail involvement is uncommon in these autoimmune blistering disorders.

Aims And Objectives: To study nail changes in autoimmune blistering disorders. Read More

View Article
September 2018
2 Reads